Supreme Court Copaxone decision could decide balance of power
This article was originally published in Scrip
Executive Summary
A case heard by the US Supreme Court on 15 October involving the validity of the single remaining patent on Teva's multiple sclerosis drug Copaxone (glatiramer acetate) essentially comes down to a balance of power question, said Oklahoma City lawyer Doug Sorocco, director and shareholder at Dunlap Codding.